Immuno-Oncology

Thomas F. Gajewski, MD, PhD, discusses how the combination of PD-1 and IDO inhibitors could change the standard of care for patients with melanoma, and highlights other emerging targets on the horizon.

Susan F. Slovin, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the current role of immunotherapy in patients with advanced prostate cancer.

Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, University of Chicago Medical Center, chair, Department of Medicine, University of Chicago Medicine, discusses biomarkers for immunotherapy in head and neck cancer.

Jason J. Luke, MD, discusses adjuvant therapy for patients with melanoma, as well as the future of targeted agents and immunotherapy.

Breelyn Wilky, MD, an associate professor of Medicine, Sylvester Comprehensive Cancer Care, University of Miami Health System, discusses the status of a phase II trial investigating concurrent axitinib (Inlyta) and pembrolizumab (Keytruda) in patients with advanced alveolar soft part sarcoma and other soft tissue sarcomas.

As the number of tumor types with approved PD-1/PD-L1 pathway inhibitors continues to expand, bladder cancer has become a robust area of development.

Jason J. Luke, MD, assistant professor of Medicine, The University of Chicago Medicine, discusses some of the ongoing adjuvant therapies in development for patients with melanoma. Luke shared this insight during the 2017 OncLive State of the Science Summit on Melanoma and Immuno-Oncology.

Investigators are looking into a novel immunotherapy combination that pairs the first-in-class IDO1 inhibitor epacadostat (INCB024360) with the checkpoint blockade agent pembrolizumab (Keytruda) in patients with unresectable or metastatic melanoma.

Giuseppe Curigliano, MD, PhD, head of the Division of Early Drug Development at European Institute of Oncology, in Milan, Italy, discusses the emergence of immunotherapy in breast cancer.

Immunotherapy will be most effective as a treatment for breast cancer when it is used to alter the tumor microenvironment, according to a careful examination of studies exploring the immune response presented by Nora Disis, MD.

Giuseppe Curigliano, MD, PhD, discusses recent trials of immunotherapy and chemotherapy in triple-negative breast cancer, as well as the future role of immunotherapy in the treatment of breast cancer.